Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Synovial sarcoma (SS) is a rare and aggressive mesenchymal malignancy driven by a unique chromosomal translocation that generates the expression of the SS18:SSX fusion protein. It occurs at almost any anatomical site and most commonly in young adults. The standard curative treatment for primary SS is a wide surgical resection combined with radiotherapy and/or neoadjuvant chemotherapy. The prognosis of SS varies among patients, with the 5 years survival rate ranging from 50 to 60% in adults and 90% in children. Although patient-derived cell lines are a useful resource for the development of new therapies, only a few are available from public cell banks. Therefore, this study aimed to establish and characterize a novel SS cell line. We successfully established a novel cell line, NCC-SS5-C1, harboring an SS18-SSX1 fusion gene. NCC-SS5-C1 cells demonstrated constant growth and invasion ability. We performed integrative drug screening using eight SS cell lines, including NCC-SS5-C1 cells, and examined the response spectrum of existing anticancer agents. We conclude that NCC-SS5-C1 is a useful resource for studying SS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Soft tissue and bone tumours. 4th ed. Geneva: WHO Press; 2020.

    Google Scholar 

  2. Schaefer IM, Hornick JL. SWI/SNF complex-deficient soft tissue neoplasms: an update. Semin Diagn Pathol. 2021;38:222–31.

    Article  Google Scholar 

  3. Bean GR, Kremer JC, Prudner BC, et al. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death Dis. 2016;7: e2406.

    Article  CAS  Google Scholar 

  4. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71–85.

    Article  CAS  Google Scholar 

  5. Sápi Z, Papp G, Szendrői M, et al. Epigenetic regulation of SMARCB1 By miR-206, -381 and -671–5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. Genes Chromosomes Cancer. 2016;55:786–802.

    Article  Google Scholar 

  6. Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015;113:1602–6.

    Article  Google Scholar 

  7. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115:2988–98.

    Article  Google Scholar 

  8. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol. 2005;27:215–8.

    Article  Google Scholar 

  9. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14:8191–7.

    Article  CAS  Google Scholar 

  10. von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:758–86.

    Article  Google Scholar 

  11. Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015;26:567–72.

    Article  CAS  Google Scholar 

  12. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040–50.

    Article  Google Scholar 

  13. Takenaka S, Ueda T, Naka N, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep. 2008;19:467–76.

    PubMed  Google Scholar 

  14. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology, and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–47.

    Article  Google Scholar 

  15. Naing KW, Monjazeb AM, Li CS, et al. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: a SEER analysis. J Surg Oncol. 2015;111:158–64.

    Article  Google Scholar 

  16. Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:1173–80.

    Article  Google Scholar 

  17. Stacchiotti S, Van Tine BA. Synovial sarcoma: current concepts and future perspectives. J Clin Oncol. 2018;36:180–7.

    Article  CAS  Google Scholar 

  18. Naka N, Takenaka S, Araki N, et al. Synovial sarcoma is a stem cell malignancy. Stem cells (Dayton, Ohio). 2010;28:1119–31.

    Article  CAS  Google Scholar 

  19. Sonobe H, Manabe Y, Furihata M, et al. Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest. 1992;67:498–505.

    CAS  PubMed  Google Scholar 

  20. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977;58:209–14.

    Article  CAS  Google Scholar 

  21. Bairoch A. The cellosaurus, a cell-Line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  22. Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 2015;14:2452–62.

    Article  CAS  Google Scholar 

  23. Kito F, Oyama R, Takai Y, et al. Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. Hum Cell. 2018;31:167–74.

    Article  CAS  Google Scholar 

  24. Oyama R, Kito F, Sakumoto M, et al. Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1. In Vitro Cell Dev Biol Anim. 2018;54:392–9.

    Article  CAS  Google Scholar 

  25. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2020. https://doi.org/10.1007/s13577-020-00354-6.

    Article  PubMed  Google Scholar 

  26. Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2021;34:998–1007.

    Article  CAS  Google Scholar 

  27. Kawai A, Naito N, Yoshida A, et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 2004;204:105–13.

    Article  CAS  Google Scholar 

  28. Xie Y, Skytting B, Nilsson G, et al. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p1.12;q1.12) translocation. Cancer Res. 2002;62:3861–7.

    CAS  PubMed  Google Scholar 

  29. Casali PG, Bruzzi P, Bogaerts J, Blay JY. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26:300–6.

    Article  CAS  Google Scholar 

  30. Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2021;112:953–61.

    Article  CAS  Google Scholar 

  31. Kondo T. Current status and perspectives of patient-derived rare cancer models. Hum Cell. 2020;33:919–29.

    Article  Google Scholar 

  32. De Vita A, Recine F, Miserocchi G, et al. The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models. J Exp Clin Cancer Res. 2021;40:165.

    Article  Google Scholar 

  33. Gatzweiler C, Ridinger J, Herter S, et al. Functional therapeutic target validation using pediatric zebrafish xenograft models. Cancers. 2022. https://doi.org/10.3390/cancers14030849.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kawaguchi K, Igarashi K, Miyake K, et al. Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. J Drug Target. 2019;27:211–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate the technical support provided by Mesdames Yu Kuwata and Rina Sasaki (Division of Rare Cancer Research, National Cancer Center). We appreciate Takshi Kondo (Hokkaido University School of Medicine) for data mining about cell lines. We thank Editage (www.editage.jp) for their English language editing services and constructive comments on the manuscript. This study was technically assisted by the Fundamental Innovative Oncology Core of the National Cancer Center.

Funding

This research was supported by the Japan Agency for Medical Research and Development (Grant number: 20ck0106537h0002).

Author information

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Takuya Ono, Taro Akiyama, Naoki Kojima & Tadashi Kondo

  2. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Naoki Kojima & Akihiko Yoshida

  3. Department of Diagnosis Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Jun Sugaya, Naoki Kojima & Akira Kawai

Authors
  1. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yooksil Sin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Taro Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Sugaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naoki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The ethics committee of the National Cancer Center approved the use of clinical materials for this study (approval numbers 2004-050).

Informed consent

Written informed consent for publication was provided by the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshimatsu, Y., Noguchi, R., Sin, Y. et al. Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma. Human Cell 35, 1290–1297 (2022). https://doi.org/10.1007/s13577-022-00721-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-022-00721-5

Keywords

Search

Navigation